How to control lymphangiogenesis: a novel role for rapamycin.
Analysis of the lymphatic microvasculature has become possible only recently by the discovery of novel proteins specifically expressed in lymphatic endothelial cells only. Therapeutic manipulation of de novo lymphangiogenesis might become clinically relevant in the future in diverse situations, such as renal transplant rejection. In this issue Huber et al. demonstrate that rapamycin acts as an efficient inhibitor of lymphangiogenesis.